Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis
Open Access
- 1 January 2014
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 6 (6) , 394-409
Abstract
Systemic lupus erythematosus (SLE) encompass a broad spectrum of liver diseases. We propose here to classify them as follows: (1) immunological comorbilities (overlap syndromes); (2) non-immunological comorbilities associated to SLE; and (3) a putative liver damage induced by SLE itself, referred to as "lupus hepatitis". In the first group, liver injury can be ascribed to overlapping hepatopathies triggered by autoimmune mechanisms other than SLE occurring with higher incidence in the context of lupus (e.g., autoimmune hepatitis, primary biliary cirrhosis). The second group includes non-autoimmune liver diseases, such as esteatosis, hepatitis C, hypercoagulation state-related liver lesions, hyperplasic parenchymal and vascular lesions, porphyria cutanea tarda, and drug-induced hepatotoxicity. Finally, the data in the literature to support the existence of a hepatic disease produced by SLE itself, or the occurrence of a SLE-associated prone condition that increases susceptibility to acquire other liver diseases, is critically discussed. The pathological mechanisms underlying each of these liver disorders are also reviewed. Despite the high heterogeneity in the literature regarding the prevalence of SLE-associated liver diseases and, in most cases, lack of histopathological evidence or clinical studies large enough to support their existence, it is becoming increasingly apparent that liver is an important target of SLE. Consequently, biochemical liver tests should be routinely carried out in SLE patients to discard liver disorders, particularly in those patients chronically exposed to potentially hepatotoxic drugs. Diagnosing liver disease in SLE patients is always challenging, and the systematization of the current information carried out in this review is expected to be of help both to attain a better understanding of pathogenesis and to build an appropriate work-up for diagnosis.Keywords
This publication has 143 references indexed in Scilit:
- Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profileBMC Medicine, 2013
- Low-dose cyclophosphamide-induced acute hepatotoxicityAmerican Journal of Case Reports, 2013
- 1342 LIVER INJURY FOLLOWING ANTI-TNF-ALPHA PEPTIDES: EXPERIENCE OF THE US DRUG-INDUCED LIVER INJURY NETWORK (DILIN) AND CRITICAL REVIEW OF PUBLISHED REPORTSJournal of Hepatology, 2012
- Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E InitiativeAnnals of the Rheumatic Diseases, 2009
- Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature researchAnnals of the Rheumatic Diseases, 2009
- Metaanalysis of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms Affecting Methotrexate ToxicityThe Journal of Rheumatology, 2009
- Osteopontin and Systemic Lupus Erythematosus Association: A Probable Gene-Gender InteractionPLOS ONE, 2008
- Hepatitis C virus (HCV) infection and systemic lupus erythematosus (SLE)Journal of Hepatology, 2000
- Hepatitis C virus infection complicating lupus nephritisNephrology Dialysis Transplantation, 1996
- Association between Lupus Psychosis and Antiribosomal P Protein AntibodiesNew England Journal of Medicine, 1987